Skip to main content
رجوع
KKPCF logo

Kaken Pharmaceutical Co., Ltd.

جودة البيانات: 100%
ذروة شراء
KKPCF
OTC Healthcare Drug Manufacturers - Specialty & Generic
KWD 26.00
KWD 0.00 (0.00%)
القيمة السوقية: 984.58M
نطاق اليوم
KWD 22.30 KWD 26.00
نطاق 52 أسبوعًا
KWD 22.30 KWD 28.12
حجم التداول
2
متوسط 50 يوم / 200 يوم
KWD 26.04 / KWD 26.36
الإغلاق السابق
KWD 26.00

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 0.1 0.3
P/B 0.0 2.9
ROE % 9.4 3.7
Net Margin % 14.8 3.8
Rev Growth 5Y % 5.8 10.0
D/E 0.0 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 79.795
KWD 72.493 – KWD 85.090
71 B 1
FY2029 KWD 66.796
KWD 60.683 – KWD 71.228
73 B 1
FY2028 KWD 39.169
KWD 35.584 – KWD 41.768
80 B 1

النقاط الرئيسية

Revenue grew 5.82% annually over 5 years — modest growth
Earnings grew 73.77% over the past year
Debt/Equity of 0.03 — conservative balance sheet
Generating 25.39B in free cash flow
P/E of 0.07 — trading at a low valuation
PEG of 0.15 suggests growth is underpriced

النمو

Revenue Growth (5Y)
5.82%
Revenue (1Y)30.52%
Earnings (1Y)73.77%
FCF Growth (3Y)89.81%

الجودة

Return on Equity
9.41%
ROIC10.08%
Net Margin14.83%
Op. Margin22.37%

الأمان

Debt / Equity
0.03
Current Ratio3.67
Interest Coverage751.21

التقييم

P/E Ratio
0.07
P/B Ratio0.01
EV/EBITDA-2.34
Dividend Yield0.05%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 30.52% Revenue Growth (3Y) 13.51%
Earnings Growth (1Y) 73.77% Earnings Growth (3Y) 60.11%
Revenue Growth (5Y) 5.82% Earnings Growth (5Y) 0.99%
Profitability
Revenue (TTM) 94.04B Net Income (TTM) 13.95B
ROE 9.41% ROA 7.32%
Gross Margin 62.24% Operating Margin 22.37%
Net Margin 14.83% Free Cash Flow (TTM) 25.39B
ROIC 10.08% FCF Growth (3Y) 89.81%
Safety
Debt / Equity 0.03 Current Ratio 3.67
Interest Coverage 751.21 Dividend Yield 0.05%
Valuation
P/E Ratio 0.07 P/B Ratio 0.01
P/S Ratio 0.01 PEG Ratio 0.15
EV/EBITDA -2.34 Dividend Yield 0.05%
Market Cap 984.58M Enterprise Value -49.26B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 94.04B 72.04B 72.98B 76.03B 74.98B
Net Income 13.95B 8.03B 5.44B 9.55B 13.41B
EPS (Diluted) 365.42 212.66 144.79 251.44 347.37
Gross Profit 58.53B 38.54B 39.56B 41.58B 40.91B
Operating Income 21.03B 9.51B 8.00B 17.06B 17.79B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 190.42B 171.62B 166.33B 165.18B 163.33B
Total Liabilities 37.79B 27.87B 29.49B 26.86B 27.08B
Shareholders' Equity 152.63B 143.76B 136.26B 137.75B 136.26B
Total Debt 3.85B 3.85B 3.85B 3.85B 3.85B
Cash & Equivalents 54.09B 50.63B 59.56B 61.03B 63.71B
Current Assets 111.38B 106.97B 109.90B 110.61B 113.66B
Current Liabilities 30.35B 19.02B 20.84B 19.05B 21.28B

درجات الاستراتيجيات

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
#97 of 1052
71
#473 of 827
38
#385 of 618
27

النشاط الأخير

دخل Cash Flow Compounder
Mar 24, 2026
دخل Deep Value Investing (Seth Klarman)
Mar 24, 2026
دخل Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
دخل Defensive Investing (Benjamin Graham)
Mar 24, 2026